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Abstract
OBJECTIVE—To explore the associations between serum concentrations of vitamin D 
(25(OH)D) and all-cause mortality among US adults defined by lung function (LF) status, 
particularly among adults with obstructive LF (OLF).
METHODS—Data from 10 795 adults aged 20–79 years (685 with restrictive LF (RLF) and 1309 
with OLF) who participated in the Third National Health and Nutrition Examination Survey 
(1988–1994), had a spirometric examination, and were followed through 2006 were included.
RESULTS—During 14.2 years of follow-up, 1792 participants died. Mean adjusted 
concentrations of 25(OH)D were 75.0 nmol/l (s.e. 0.7) for adults with normal LF (NLF), 70.4 
nmol/l (s.e. 1.8) for adults with RLF, 75.5 nmol/l (s.e. 1.5) for adults with mild obstruction and 
71.0 nmol/l (s.e. 1.9) among adults with moderate or worse obstruction (P = 0.030). After 
adjustment for sociodemographic factors, lifestyle factors, clinical variables and prevalent chronic 
conditions, a concentration of <25 nmol/l compared with ≥75 nmol//l was associated with 
mortality only among adults with NLF (hazard ratio (HR) 1.76; 95% confidence interval (CI) 1.03, 
3.00). Among participants with OLF, adjusted HRs were 0.65 (95% CI 0.29, 1.48), 1.21 (95% CI 
0.89, 1.66) and 0.97 (95% CI 0.78, 1.19) among those with concentrations <25, 25–<50 and 50–
<75 nmol/l, respectively.
CONCLUSIONS—Baseline concentrations of 25(OH)D did not significantly predict mortality 
among US adults with impaired LF.
INTRODUCTION
Chronic obstructive pulmonary disease is a major source of morbidity and mortality in the 
United States.1 In 2011, 6.3% of adults reported having chronic obstructive pulmonary 
disease.2 In 2010, 10.3 million outpatient visits for chronic obstructive pulmonary disease 
were made, 1.5 million visits to emergency department were made, and almost 700 000 
hospital discharges were recorded.1 In 2008, chronic lower respiratory disease became the 
third leading cause of death.3 Because adults with chronic obstructive pulmonary disease are 
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at increased risk for mortality from all-causes and cardiovascular disease,4–7 identifying 
potential approaches to lessen mortality among adults with chronic obstructive pulmonary 
disease is of clinical and public health relevance.
Trials of supplementation with vitamin D have yielded mixed evidence of its effects on all-
cause mortality and incidence and mortality from cardiovascular disease.8–15 A recent 
review of systematic reviews and meta-analyses concluded that the relationships between 
concentrations of vitamin D, supplementation with vitamin D, and a range of health 
outcomes remain largely clouded in uncertainty.16 Nevertheless, adequate vitamin D status 
may lessen the risk for developing respiratory infections, a finding that may be especially 
relevant to people with chronic obstructive pulmonary disease among whom exacerbations, 
often due to respiratory infections, adversely affect their clinical course as manifested by 
increased morbidity and mortality.17–24 Vitamin D has anti-inflammatory, anti-infectious 
and immunomodulating properties that are potentially highly relevant in the setting of 
chronic obstructive pulmonary disease, a disease commonly triggered by environmental 
exposures and infectious agents and characterized by inflammation, oxidative stress and 
exacerbations due to respiratory infections.25
These considerations suggested that circulating concentrations of vitamin D could be 
inversely related to all-cause mortality among adults with evidence of obstructive airways 
disease on pulmonary function testing. However, this domain of research remains largely 
unexplored although recently several studies have failed to show that concentrations of 
25(OH)D predicted mortality in patients with chronic obstructive pulmonary disease.26–28 
Thus, the objective of this study was to examine the prospective association between 
circulating concentrations of vitamin D (25 (OH)D) and all-cause mortality in a national 
sample of adults with obstructive lung function (LF). Secondary objectives included 
examining the prospective association between circulating concentrations of 25(OH)D and 
all-cause mortality among adults with restrictive LF (RLF) and among all participants.
MATERIALS AND METHODS
This study used public use data from the Third National Health and Nutrition Examination 
Survey (NHANES III) Linked Mortality Study (baseline examination from 1988 through 
1994; follow-up through 2006).29 A stratified multistage probability sample was used to 
select a sample that was representative of the civilian non-institutionalized population in the 
United States. After agreeing to participate in the survey, participants were interviewed in 
their homes. Those who accepted an invitation to have an examination completed additional 
questionnaires, underwent a series of examinations, and provided blood and urine specimens 
in the mobile examination center. The interview and examination response rates were 86 and 
78%, respectively. NHANES III received Institutional Review Board Approval.
Deaths were identified though a probabilistic match of participants’ information with 
National Death Index death certificate records. Participants whose attempted match did not 
lead to the identification of a death were considered to be alive.
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A pulmonary function test was administered to adults, and no post-bronchodilator testing 
was performed. A detailed description of the procedures used to conduct spirometry can be 
found elsewhere.30 Borrowing from the GOLD (Global Initiative for Chronic Obstructive 
Lung Disease classification), four categories of LF were established: normal LF (NLF), RLF 
(forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) ≥0.70 and 
FVC <80% predicted), mild obstructive LF (OLF) (FEV1/FVC <0.70 and FEV1 ≥80%), 
moderate OLF (FEV1/FVC <0.70 and FEV1 50 to <80% predicted) and severe OLF 
(FEV1/FVC <0.70 and FEV1 <50% predicted). To increase sample size, participants with 
moderate or severe OLF were combined for some descriptive analyses of concentrations of 
25(OH)D, and participants with any OLF were combined for analyses involving estimation 
of risk for mortality.
Serum concentrations of 25-hydroxyvitamin D or 25(OH)D were measured using a 
radioimmunoassay method (DiaSorin, Stillwater, MN, USA).16 Details about the methods 
including quality control procedures and results can be found elsewhere.31 For some 
analyses, 25(OH)D was classified into four categories <25, 25–<50, 50–<75 and ≥75 nmol/
l.32 In addition, concentrations of 25(OH)D were categorized into three categories <30, 30–
<50 and ≥50 nmol/l.33
Covariates included age, gender, self-reported race or ethnicity (white, African American 
and other), educational level, smoking status, alcohol use, leisure-time physical activity, use 
of vitamin or mineral supplements, systolic blood pressure, high-density lipoprotein 
cholesterol, non-high-density lipoprotein cholesterol, body mass index, C-reactive protein, 
urinary albumin-creatinine ratio, health status, diabetes and histories of myocardial 
infarction and stroke.
Three categories of smoking status were established: current smokers (participants who had 
smoked ≥100 cigarettes during their lifetime and were still smoking), former smokers 
(participants who had smoked ≥100 cigarettes during their lifetime but had stopped) and 
never having smoked (participants who had smoked <100 cigarettes during their lifetime 
were classified as having never smoked). The frequency of alcohol consumption was 
estimated from answers to questions about the number of times per month a participant had 
consumed beer, wine, or spirits. Four levels of physical activity were defined: vigorous 
activity (participating three or more times per week in an activity with a metabolic 
equivalent level of ≥6 for participants who were 60 years or older and ≥7 metabolic 
equivalents for participants who were younger than 60 years), moderate activity 
(participating five or more times per week in activities of which no more than two could be 
considered vigorous activities), light activity (participation that was not vigorous or 
moderate), and sedentary (engaging in no leisure-time physical activity). The use of 
vitamins or minerals was assessed with the question ‘Have you taken any vitamins or 
minerals in the past month?’
The average of the second and third systolic blood pressure measurement was used in the 
analyses. Measured weight and height was used to calculate body mass index (weight in 
kilograms divided by height in meters squared). Following the precipitation of other 
lipoproteins with a heparin-manganese chloride mixture, concentrations of high-density 
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lipoprotein cholesterol were measured on a Hitachi 704 Analyzer (Boehringer Mannheim 
Diagnostics, Indianapolis, IN, USA). Concentrations of non-high-density lipoprotein 
cholesterol were calculated by subtracting the concentration of high-density lipoprotein 
cholesterol from that of total cholesterol. Serum C-reactive protein was measured by using 
latex-enhanced nephelometry on a Behring Nephelometer Analyzer System (BNA) (Behring 
Diagnostics Inc., Somerville, NJ, USA). Urinary albumin was measured on a Sequoia-
Turner Fluoremeter (Sequoia-Turner Corp., Mountain View, CA, USA) with a fluorescent 
immunoassay. Urinary creatinine was measured on a Beckman Synchron AS/ASTRA 
clinical analyzer (Beckman Instruments Inc., Brea, CA, USA).
Health status was assessed with the question ‘Would you say your health in general is 
excellent, very good, good, fair or poor?’. Diabetes was defined as a positive response to the 
question ‘Have you ever been told by a doctor that you have diabetes or sugar diabetes?’ or 
a concentration of HbA1c ≥ 6.5%. Positive responses to the questions ‘Has a doctor ever 
told you that you had a heart attack?’; and ‘Has a doctor ever told you that you had a 
stroke?’ were used to identify participants with histories of myocardial infarction or stroke, 
respectively.
The analyses were limited to men and non-pregnant women aged 20–79 years who had a 
spirometric examination in the mobile examination center and reproducible FEV1 and FVC 
results. Participants with self-reported asthma were excluded (‘Has a doctor ever told you 
that you had asthma?’). Mortality rates per 1000 person-years of survival time were 
calculated. Age adjustment was done to the projected year 2000 US population for adults 
aged 20–79 years using the direct method. Least-square adjusted mean concentrations of 
25(OH)D by categories of LF status were calculated, and P-values for differences in 
concentrations were estimated from linear regression results. Proportional hazards analysis 
was used to estimate hazard ratios (HRs) for mortality according to categories of 25(OH)D 
concentrations for the entire sample and for groups stratified by LF status. Analyses were 
conducted in SAS and SUDAAN, the latter to account for the complex sampling design of 
the surveys.
RESULTS
Of the 15 331 participants aged 20–79 years, 10 were ineligible because information needed 
to determine their follow-up status was not available. Eliminating pregnant women reduced 
the sample size to 15 033. Limiting the sample to participants with acceptable spirometric 
maneuvers left 13 134 participants, a number that was further reduced to 12 235 after 
excluding participants with self-reported asthma. Additional reductions due to participants 
with missing information for other study variables resulted in an analytic sample of 10 795 
participants.
The analytic sample included 5263 men, 5532 women, 4348 whites, 2908 African 
Americans, 3112 Mexican Americans and 427 of another race or ethnicity. Overall, 79.9% 
(s.e. 0.6) had NLF, 6.5% (s.e. 0.4) had RLF and 13.6% (s.e. 0.6) had OLF. The mean 
concentration of 25(OH)D was 74.5 nmol/l, and the median concentration was 71.6 nmol/l.
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The mean and median lengths of follow-up were 14.2 and 14.5 years, respectively. In all, 
1792 participants died (1012 of 8801 adults with normal pulmonary function, 208 of 685 
adults with an RLF and 572 of 1309 adults with any OLF).
Numerous differences of means and percentages of study variables were present between 
survivors and decedents (Table 1). However, the age-adjusted means of concentrations of 
25(OH)D did not differ significantly. In addition, numerous differences in study variables 
among the three groups of respiratory function status were present.
25(OH)D concentrations and pulmonary function status
Adjusted mean concentrations of 25(OH)D in participants with RLF were significantly 
lower than that of persons with normal function (P = 0.016) (Table 2). However adjusted 
mean concentrations among those with moderate–severe (P = 0.043) but not mild (P =0. 
736) OLF differed significantly from mean concentrations of participants with normal 
pulmonary function. The age-adjusted percentages of 25(OH)D deficiency (<50 nmol/l) for 
the four groups were 20.7% (s.e. 1.1) for participants with normal pulmonary function, 
32.1% (s.e. 2.8) for participants with RLF, 16.6% (s.e. 2.8) for participants with mild OLF 
and 20.8% (s.e. 3.3) for participants with moderate–severe OLF. The percentage of 25 
(OH)D deficiency among participants with RLF was significantly higher compared with 
each of the three other categories (all P < 0.050). Using a threshold for 25(OH)D deficiency 
of <30 nmol/l, 3.2% (s.e. 0.3) of participants with normal LF, 6.0% (s.e. 1.4) of participants 
with restrictive LF, 4.6% (s.e. 1.5) of participants with mild OLF and 3.0% (s.e. 0.8) of 
participants with moderate or worse OLF were considered as deficient. No significant 
differences among these estimates were observed.
25(OH)D concentrations and mortality among all participants
In models adjusted for sociodemographic variables, concentrations of 25(OH)D as a 4-level 
variable were significantly associated with all-cause mortality (Table 3). In the fully 
adjusted model, however, concentrations of 25(OH)D lost statistical significance (P-adjusted 
Wald F test = 0.179). In models using 25(OH)D as a 3-level variable, 25(OH)D was 
significantly associated with mortality in all models (Table 4). Concentrations of 25(OH)D 
modeled as a continuous variable were not significantly associated with mortality (P-
adjusted Wald F = 0.268), but the squared term for concentrations of 25(OH)D was 
significant (P-adjusted Wald F = 0.011) suggesting a non-linear association (Supplementary 
Table 1).
25(OH)D and mortality by pulmonary function status
Among participants with normal pulmonary function, a significant association between 
25(OH)D and mortality was noted for the first two models (Table 3). In the fully adjusted 
model, an elevated and significant HR was noted for participants with a concentration of 
25(OH)D <25 nmol/l compared with those with a concentration of ≥ 75 nmol/l only among 
those with NLF (adjusted HR (aHR) = 1.76; 95% confidence interval (CI): 1.03, 3.00) 
although the P-value for the global test for the 25(OH)D terms was 0.226. When the 
analyses were repeated using three categories, participants with a concentration of <30 
nmol/l had an elevated HR compared with those with a concentration of ≥50 nmol/l 
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(adjusted HR = 1.63, 95% CI 1.03, 2.58) (Table 4). Among participants with either OLF or 
RLF, there was no evidence to suggest that a concentration of 25(OH)D <50 or <30 nmol/L 
was significantly associated with mortality (Tables 3 and 4). No interaction between 
pulmonary function status and concentrations of 25(OH)D as the 4-category variable (P 
interaction = 0.464) or as the 3-category variable (P interaction = 0.756) was noted. Results 
for models in which 25(OH)D was modeled as a continuous variable are presented in 
Supplementary Table 1.
DISCUSSION
In this cohort, baseline mean concentrations of 25(OH)D were significantly lower among 
participants with RLF and moderate or worse OLF than among participants with NLF or 
mild OLF. Furthermore, concentrations of 25(OH)D <25 nmol/l compared with ≥ 75 nmol/l 
among adults with an NLF, but not those with impaired LF, were significantly associated 
with mortality. Because limited information about possible health benefits of adequate 
vitamin D status in adults with OLF is available, the results of the present study add to a 
meager evidence base in an area of growing interest.
Several previous analyses of the relationship between concentrations of 25(OH)D and 
mortality using NHANES III data have been conducted.34–36 In an analysis of 13 331 adults 
aged ≥ 20 years with mortality through the year 2000, those in the lowest quartile of 
25(OH)D were at slightly increased risk of death (aHR 1.26, 95% CI: 1.08–1.46).34 These 
results were adjusted for age, sex, race, season, hypertension, history of CVD, diabetes 
mellitus, smoking, body mass index, high-density lipoprotein cholesterol, total cholesterol, 
the use of cholesterol-lowering medications, estimated glomerular filtration rate categories, 
serum albumin level, log urinary albumin-to-creatinine ratio, C-reactive protein, physical 
activity level, vitamin supplementation and low socioeconomic status. A subsequent 
analysis limited to 3408 adults aged ≥ 65 years reported a significant inverse association 
between 25(OH)D and all-cause mortality (aHR 0.95 per 10 nmol/l, 95% CI: 0.92–0.98). 
The follow-up was also conducted through the year 2000.35 More recently, another analysis 
of 13 131 participants aged 35–74 years with mortality followed through 2006 found an 
elevated risk for mortality among participants with concentrations of <20 ng/ml compared 
with those with a concentration of ≥30 ng/ml (aHR 1.40, 95% CI: 1.17–1.68).36 The model 
was adjusted for age, gender, race or ethnicity, marital status, education, smoking status, 
alcohol intake, physical activity, body mass index and diabetes. The results of the present 
study among adults with NLF are broadly consistent with the latter publication.
Although reasons to suspect that adequate vitamin D concentrations could be particularly 
beneficial in adults with chronic obstructive pulmonary disease or OLF, no evidence in the 
present study was observed suggesting that adequate concentrations of 25(OH)D had a 
beneficial effect on the mortality experience of adults with OLF. In fact, the magnitude of 
the HR in this group was smaller than the HR for adults with normal pulmonary function 
although there was no statistical evidence that the associations differed among the three 
groups of pulmonary function. These results are consistent with findings from three other 
observational studies with durations of follow-up ranging from 2 to 10 years that failed to 
find significant associations between concentrations of 25(OH)D and mortality.26–28 Also, a 
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clinical trial among patients with chronic obstructive pulmonary disease did not show that 
vitamin D supplementation lowered 1-year mortality.37 Furthermore, concentrations of 
25(OH)D have not been shown to be significantly associated with exacerbations.27,37–39
Researchers continue to investigate how vitamin D status may influence respiratory health. 
Several mechanisms have been proposed to explain potential links between vitamin D 
concentrations and chronic obstructive pulmonary disease and include effects of vitamin D 
on calcium homeostasis, host defense of the airways, extracellular matrix, and muscle 
strength.25,40,41 Previous research has demonstrated a high prevalence of vitamin D 
deficiency among patients with chronic obstructive pulmonary disease as well as 
associations between concentrations of vitamin D and pulmonary function test parameters 
such as FEV1 and FVC. For example, a previous analysis of data from NHANES III showed 
that concentrations of 25(OH)D were directly associated with FEV1 and FVC.42 However, 
the authors did not apply a GOLD-like classification to these data. Thus, the current study 
approached the question of a possible association between concentrations of 25(OH)D and 
pulmonary function from a different perspective. In a study of adults aged 59–73 years in 
the United Kingdom, serum concentrations of 25(OH)D were not significantly associated 
with FEV1, FVC and FEV1/FVC but were significantly associated with spirometrically 
defined chronic obstructive pulmonary disease.43 Previous research has shown that with 
increasing severity of chronic obstructive pulmonary disease, vitamin D deficiency may 
increase.44 Because of the small number of adults with severe OLF in the present study, an 
analysis of the association between concentrations of 25(OH)D and mortality in adults with 
more severe forms of OLF was not feasible.
Several limitations deserve consideration. First, sample sizes for the groups of participants 
with RLF and OLF were considerably smaller than the sample size for participants with 
normal pulmonary function. Despite these smaller sample sizes, the numbers of deaths were 
substantial and should have been adequate for showing a modest association. Second, no 
post-bronchodilator spirometry was performed and thus the sample of participants with OLF 
also contains some percentage of participants with asthma. The exclusion of participants 
with self-reported asthma should have reduced the possible effects on the analyses of such 
participants. Third, the debate about recommended spirometric criteria for detecting OLF in 
the elderly continues. Any misclassification of elderly participants with respect to their LF 
status could have conceivably affected the results. Fourth, only a single determination of 
concentrations of 25(OH)D was done, but most cohort studies examining health outcomes 
have been performed using a single measurement. Measurements of concentrations of 
25(OH)D have shown good reproducibility over periods ranging up to 3 years.45–47 Fifth, 
although this analysis adjusted for a large number of possible confounders, residual 
confounding remains a possibility.
In conclusion, this analysis of NHANES III data found no support for the hypothesis that 
adequate concentrations of 25(OH)D might favorably impact mortality among adults with 
impaired LF. Sample sizes of studies reporting on the association between concentrations of 
25(OH)D and mortality in adults with OLF are limited, and hence additional studies are 
needed. Because vitamin D status has been linked to a host of adverse health outcomes, 
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characterizing the full spectrum of possible links between vitamin D status and morbidity 
and mortality among people with impaired LF warrants continued scientific pursuit.
Supplementary Material
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Table 4
Hazard ratios (95% confidence limits) for all-cause mortality in function of concentrations of vitamin D 
among US adults aged 20–79 years, by pulmonary function status, National Health and Nutrition Examination 
Survey III Linked Mortality Study 1988–1994 to 2006
Vitamin D (nmol/l) P-adjusted Wald F
<30 30–<50 ≥ 50
Total
  Unweighted no. of deaths 133 490 1169
  Unweighted no. at risk 794 2877 7124
  Unadjusted rate per 1000 person-years (s.e.) 12.4 (2.0) 11.1 (0.8) 8.2 (0.5)
  Age-adjusted rate per 1000 person-years (s.e.) 18.6 (2.1) 12.7 (0.9) 10.5 (0.5)
  Model 1 1.50 (1.05, 2.15) 1.34 (1.12, 1.60) 1.00 0.003
  Model 2 1.85 (1.37, 2.50) 1.30 (1.08, 1.56) 1.00 <0.001
  Model 3 1.47 (1.06, 2.04) 1.18 (0.99, 1.41) 1.00 0.044
Normal lung function
  Unweighted no. of deaths 78 278 656
  Unweighted no. at risk 654 2343 5804
  Unadjusted rate per 1000 person-years (s.e.) 8.4 (1.8) 7.4 (0.6) 5.2 (0.4)
  Age-adjusted rate per 1000 person-years (s.e.) 15.1 (2.3) 10.4 (0.8) 8.1 (0.5)
  Model 1 1.57 (0.99, 2.50) 1.39 (1.11, 1.75) 1.00 0.015
  Model 2 1.94 (1.21, 3.13) 1.34 (1.07, 1.70) 1.00 0.016
  Model 3 1.63 (1.03, 2.58) 1.17 (0.93, 1.47) 1.00 0.116
Restrictive lung function
  Unweighted no. of deaths 22 67 119
  Unweighted no. at risk 67 227 391
  Unadjusted rate per 1000 person-years (s.e.) 23.7 (8.6) 19.1 (3.2) 16.4 (2.5)
  Age-adjusted rate per 1000 person-years (s.e.) 34.4 (7.4) 16.7 (3.0) 15.6 (2.1)
  Model 1 1.46 (0.68, 3.12) 1.20 (0.75, 1.89) 1.00 0.526
  Model 2 1.37 (0.77, 2.43) 1.06 (0.66, 1.69) 1.00 0.554
  Model 3 1.07 (0.57, 2.00) 1.00 (0.65, 1.52) 1.00 0.977
Obstructive lung function
  Unweighted no. of deaths 33 145 394
  Unweighted no. at risk 73 307 929
  Unadjusted rate per 1000 person-years (s.e.) 29.4 (7.9) 32.5 (3.9) 26.9 (1.7)
  Age-adjusted rate per 1000 person-years (s.e.) 19.1 (4.2) 17.6 (2.5) 15.7 (1.3)
  Model 1 1.07 (0.61, 1.87) 1.24 (0.98, 1.58) 1.00 0.190
  Model 2 1.39 (0.83, 2.30) 1.21 (0.91, 1.60) 1.00 0.167
  Model 3 1.00 (0.57, 1.77) 1.20 (0.90, 1.62) 1.00 0.464
Model 1 is adjusted for month of examination. Model 2 is adjusted for variables in model 1 plus age, gender, race or ethnicity and education. 
Model 3 is adjusted for variables in model 2 plus smoking status, alcohol use, leisure-time physical activity, use of vitamin or mineral supplements, 
systolic blood pressure, high-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, body mass index, C-reactive protein, 
albumin–creatinine ratio, health status, diabetes, history of myocardial infarction and history of stroke.
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